MedTrace Logo

Effects of Microencapsulated Sublingual Glycine (Bidicin) on Cognitive Performance in Healthy Men After an Acute Stressor

NCT03353441 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2018-07-26

No results posted yet for this study

Summary

The aim of this study is to assess whether intake of Glycine (MSG) leads to an increase of cognitive performance after an acute stressor compared to placebo. One group will receive verum, one group placebo and one group will not receive any intervention. Cognitive testing will be performed in connection with the Trier Social Stress Test (TSST).

Conditions

Interventions

DIETARY_SUPPLEMENT

Microencapsulated Sublingual Glycine (MSG)

Glycine (MSG) tablet

DIETARY_SUPPLEMENT

Placebo

Lactose tablet manufactured to mimic Glycine (MSG) tablet

Sponsors & Collaborators

  • OOO MNPK BIOTIKI

    collaborator UNKNOWN

  • Daacro

    lead NETWORK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-15
Primary Completion
2018-03-15
Completion
2018-06-15

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03353441 on ClinicalTrials.gov